Skip to main content
. 2024 May 16;5(7):100685. doi: 10.1016/j.jtocrr.2024.100685

Table 3.

Safety Summary

AE, n (%) Avelumab + Lorlatinib (n = 31) Avelumab + Crizotinib (n = 12)
TEAE, any grade 30 (97) 12 (100)
 Grade ≥3 23 (74) 7 (58)
TRAE, any grade 28 (90) 12 (100)
 Grade ≥3 16 (52) 6 (50)
TEAE leading to permanent discontinuation of any study drug 10 (32) 6 (50)
TEAE leading to permanent discontinuation of all study drugs 1 (3) 3 (25)
TRAE leading to permanent discontinuation of avelumab 9 (29) 2 (17)
TRAE leading to permanent discontinuation of crizotinib 0 5 (42)
TRAE leading to permanent discontinuation of lorlatinib 2 (7) 0
TEAE leading to death 4 (13) 1 (8)
TRAE leading to death 1 (3) 0
IRR (AE of special interest) 9 (29) 5 (42)

AE, adverse event; IRR, infusion-related reaction; TEAE, treatment-emergent AE; TRAE, treatment-related AE.